Annual report pursuant to Section 13 and 15(d)

REVENUES, NET

v3.24.2
REVENUES, NET
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
REVENUES, NET

NOTE 3—REVENUES, NET

Revenues, net by category were as follows (in thousands):

 

 

Years ended December 31,

 

2023

 

 

2022

 

Endari®

$

28,961

 

 

$

17,854

 

Other

 

636

 

 

 

536

 

Revenues, net

 

29,597

 

 

 

18,390

 

The following table summarizes the revenue allowance and accrual activities for the years ended December 31, 2023, and 2022 (in thousands):

 

Trade Discounts, Allowances and Chargebacks

 

 

Government Rebates and Other Incentives

 

 

Returns

 

 

Total

 

Balance as of December 31, 2021

 

$

1,481

 

 

$

3,133

 

 

$

539

 

 

 

5,153

 

Provision related to sales in the current year

 

 

2,672

 

 

 

2,857

 

 

 

1,416

 

 

 

6,945

 

Adjustments related to prior period sales

 

 

(56

)

 

 

18

 

 

 

537

 

 

 

499

 

Credit and payments made

 

 

(2,739

)

 

 

(2,290

)

 

 

(2,077

)

 

 

(7,106

)

Balance as of December 31, 2022

 

 

1,358

 

 

 

3,718

 

 

 

415

 

 

 

5,491

 

Provision related to sales in the current year

 

 

2,402

 

 

 

4,790

 

 

 

1,027

 

 

 

8,219

 

Adjustments related to prior period sales

 

 

(176

)

 

 

135

 

 

 

73

 

 

 

32

 

Credit and payments made

 

 

(2,372

)

 

 

(2,985

)

 

 

(652

)

 

 

(6,009

)

Balance as of December 31, 2023

 

$

1,212

 

 

$

5,658

 

 

$

863

 

 

$

7,733

 

The following table summarizes revenue attributable to each of the customers that accounted for 10% or more of net revenues in either of the period shown:

 

 

Years Ended December 31,

 

 

2023

 

 

2022

 

Customer A

 

 

21

%

 

 

25

%

Customer B

 

 

22

%

 

 

27

%

Customer C

 

 

11

%

 

 

14

%

Customer D

 

 

14

%

 

 

13

%

Customer E

 

 

10

%

 

 

3

%

Total

 

 

78

%

 

 

82

%

The Company is a party to a 2017 distributor agreement and 2018 amended distributor agreement with Telcon RF Pharmaceutical, Inc., or Telcon, pursuant to which it granted Telcon exclusive rights to the Company’s prescription grade L‑glutamine (“PGLG”) oral powder for the treatment of diverticulosis in South Korea, Japan and China in exchange for Telcon’s payment of a $10 million upfront fee and agreement to purchase from the Company specified minimum quantities of the finished product. In a related license agreement with Telcon, the Company agreed to use commercially reasonable best efforts to obtain product registration in these territories within three years of obtaining FDA marketing authorization for PGLG in this indication. Telcon has the right to terminate the distributor agreement in certain circumstances for failure to obtain such product registrations, in which event the Company would be obliged to repay Telcon the $10 million upfront fee. The upfront fee of $10 million is included as unearned revenue in other current liabilities as of December 31, 2023 and 2022. Refer to Notes 11 and 12 for additional details of the Company’s agreements with Telcon.